Clinical Trial Update: Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating safety and dosage of a computerized cognitive training program for cognitive dysfunction following COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Dysfunction
• Cognitive Impairment
• Post-acute COVID-19
• Post-acute COVID-19 Syndrome

Drugs mentioned

• Computerized Cognitive Training Program

Snippet

Sponsor: Universidad Antonio de Nebrija | Conditions: Post-Acute COVID-19, Post Acute COVID-19 Syndrome | Phase 1, Phase 2 | Status: UNKNOWN